n/a
Article Publish Status: FREE
Abstract Title:

Salvia miltiorrhiza enhances the survival of mesenchymal stem cells under ischemic conditions.

Abstract Source:

J Pharm Pharmacol. 2018 Sep ;70(9):1228-1241. Epub 2018 Jun 25. PMID: 29943504

Abstract Author(s):

Ran Kim, Seokyeon Lee, Chang Youn Lee, Hwayoung Yun, Hojin Lee, Min Young Lee, Jongmin Kim, Jee-Yeong Jeong, Kyungmin Baek, Woochul Chang

Article Affiliation:

Ran Kim

Abstract:

OBJECTIVES: To validate the enhanced therapeutic effect of Salvia miltiorrhiza Bunge (SM) for brain ischemic stroke through the anti-apoptotic and survival ability of mesenchymal stem cells (MSCs).

METHODS: The viability and the expression level of cell apoptotic and survival-related proteins in MSCs by treatment of SM were assessed in vitro. In addition, the infarcted brain region and the behavioural changes after treatment of MSCs with SM were confirmed in rat middle cerebral artery occlusion (MCAo) models.

KEY FINDINGS: We demonstrated that SM attenuates apoptosis and improves the cell viability of MSCs. In the rat MCAo model, the recovery of the infarcted region and positive changes of behaviour are observed after treatment of MSCs with SM.

CONCLUSIONS: The therapy using SM enhances the therapeutic effect for brain ischemic stroke by promoting the survival of MSCs. This synergetic effect thereby proposes a new experimental approach of traditional Chinese medicine and stem cell-based therapies for patients suffering from a variety of diseases.

Study Type : Animal Study, In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.